Navigation Links
Sharp HealthCare Selects MEDai's Pinpoint Review to Prevent Readmissions
Date:10/14/2009

ORLANDO, Florida, October 14 /PRNewswire/ --

- Baldridge Award Winner Builds on Results of Pinpoint Quality(R)/ Pinpoint Compliance(R)

MEDai, Inc., an Elsevier company and leading provider of advanced healthcare solutions including hospital outcomes analysis and award-winning predictive analytics, has announced that Sharp HealthCare, a 1,700-bed, seven-facility system serving the San Diego area, has selected the company's Pinpoint Review(TM) product. The solution is designed to alert providers to patients at risk for developing hospital acquired conditions or at risk for readmission.

Sharp will use Pinpoint Review to support quality improvement and The Sharp Experience, a sweeping performance improvement initiative launched in 2001. Pinpoint Review will provide Sharp with near-time triggers for core measures, hospital/system-wide surveillance of safety risks, physician performance reporting and forecasts of readmissions.

"Sharp's selection of Pinpoint Review is based on our personal experience with the prebuilt measures of clinical performance and ease of use found within two other MEDai tools, Pinpoint Quality and Pinpoint Compliance," said Nancy G. Pratt, RN, MS, Sharp's Senior Vice-President of Clinical Effectiveness. "Collectively, these tools offer Sharp near-time access to clinical data for performance improvement, while Pinpoint Review, in particular, addresses readmissions and new and emerging clinical measures of care."

For the past nine years, Sharp has relied on MEDai's Pinpoint Quality to reduce urinary tract infection rates, reduce blood utilization, and monitor quality outcomes across diseases. MEDai's solutions also assisted Sharp in being recognized with the coveted Malcolm Baldridge National Quality Award in 2007.

"MEDai is pleased that Sharp has selected Pinpoint Review to focus on the likelihood of its patients developing complications or r
'/>"/>

SOURCE MEDai
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
2. Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
3. The Governator and the Disintegrator: A Sharp Match Holding Pharmaceutical Companies Accountable
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. ViroPharma to Present at Three Upcoming Healthcare Conferences
7. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
8. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
9. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
10. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
11. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 A new ... manage the clinical review of specialty pharmaceuticals has ... of drugs reviewed while reducing costs. ,, AIM, ... company with health plan clients representing over 35 ... Inc. (NYSE: WLP ), adapted the ...
(Date:12/16/2009)... REYKJAVIK, Iceland, December 16 Scientists at,deCODE ... journal Nature the,discovery of a version of a ... genome (SNP) with a major impact on susceptibility ... T2D variant is not only large, but unusual:,if ... variant increases risk of,T2D by more than 30% ...
(Date:12/16/2009)... NEW YORK, December 16 ... the publication of GFT505 (80 mg/day),data ... 50 internationally,recognized expert scientists and clinicians ... the continuing role of generic lipid-modifying,treatments, ... which is commonly observed in patients ...
Breaking Medicine Technology:American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3A new bent on fusion 9637 1A new bent on fusion 9637 2Princeton team learns why some drugs pack such a punch 9635 1Princeton team learns why some drugs pack such a punch 9635 2Princeton team learns why some drugs pack such a punch 9635 3ESCO Announces Major Contract Award for Its Thermoforming Business 54966 1ESCO Announces Major Contract Award for Its Thermoforming Business 54966 2
... by the European Commission, ATRIPLA Would Represent the, First and Only Once-Daily ... ... PRINCETON, N.J., FOSTER CITY, Calif. and WHITEHOUSE STATION, N.J., Oct.,18 Bristol-Myers ... and Merck & Co., Inc. (NYSE: MRK ),announced today that the ...
... Society for Reproductive Medicine meeting could significantly improve ability to identify embryos ... patients, AFA supports efforts to bring advanced screening technology to patients as,quickly as ... ... procedures, NEW YORK, Oct. 18 According to results ...
Other Medicine Technology:European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 2European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 3European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 4European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 5European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 6European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 7European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 8European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 9European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) 10American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities 2American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities 3
(Date:12/17/2009)... uniquely designed, extremely resilient, ‘two-in-one’ foam roller. This patented foam ... that is rounder, making it one of the most versatile ... ... MN (PRWEB) December 17, 2009 -- The SMARTROLLER® from ... roller. This patented foam roller has one side that is ...
(Date:12/17/2009)... quality standards. Open to primary care doctors who agree to ... reimbursement for commonly billed services, , ... ... Blue Cross and Blue Shield of North Carolina (BCBSNC) ... North Carolina by introducing a new reimbursement model for participating ...
(Date:12/17/2009)... It,s customary for the holidays to wreak havoc on ... year, workouts often get short-changed and nutrition is left ... Valerie Waters, it is not impossible to enjoy the ... California Raisins and Waters have teamed up to offer ... holiday season and get a jump start on New ...
(Date:12/17/2009)... Dec. 17 Virtual Health Technologies, Inc. ... Gold (a wholly owned operating subsidiary of VHGI) ... position to assist with evaluating potential International Mining ... decision for the role and hopes to make ... potential joint ventures and opportunities within the overseas ...
(Date:12/17/2009)... Researchers from the La Jolla Institute for Allergy & ... most dangerous infectious diseases tuberculosis, malaria and dengue ... of projects seeking to make new inroads toward vaccines ... four project awards totaling $18.8 million from the National ... the National Institutes of Health, to fund the study. ...
Breaking Medicine News(10 mins):Health News:OPTP Introduces the SMARTROLLER 2Health News:BCBSNC Rewarding Physicians for Better Care, Not More Care, Through Blue Quality Physician Program, 2Health News:BCBSNC Rewarding Physicians for Better Care, Not More Care, Through Blue Quality Physician Program, 3Health News:Celebrity Fitness Trainer Valerie Waters and California Raisins Offer Advice on How to Jump Start the New You in the New Year 2Health News:Celebrity Fitness Trainer Valerie Waters and California Raisins Offer Advice on How to Jump Start the New You in the New Year 3Health News:VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated 2Health News:VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated 3Health News:VHGI: VHGI Gold Targets Candidates to Fill Key Advisory Board Position to Evaluate International Mining Acquisitions; Internet Town Hall Meeting Details Emerge, Kitco Gold Coverage Initiated 4Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 2Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 3Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 4Health News:NIH awards La Jolla Institute $18.8 million for major infectious disease study 5
... will have to take a leaf out of China to ... pharmaceutical industry to be a global leader // , even ... of the generics market to become a regional hub for ... by KPMG International has said. ,'India needs to look ...
... Economic losses brought by AIDS to China in the coming ... billion), said a renowned AIDS expert here Wednesday//. ,At ... Yi, chief scientist with the STD (sexually-transmitted diseases) and AIDS ... of human resources caused by AIDS in China are estimated ...
... potentially lethal in itself, a more potent menace is ... to a higher casualty rate among drug users in ... ,'The 'impure' drugs are more dangerous as quite ... presence of impurities. Especially in the case of cocaine ...
... parlance it has become mandatory for the doctors to recommend ... milk //alone for the first six months, excluding any solid ... a new study, saying that feeding the babies on cereals ... food allergies. ,Jill Poole, M.D., assistant professor in ...
... University in California, monstrous matter-sucking black holes in the space ... research//. ,When used in a car it will ... gallon (4.5 litres) of gas. ,Huge bubbles in ... or even thousands of light-years across. ,Allen and ...
... for women diagnosed with breast cancer who harbour a ... treatments to reduce their risk of a revival. ... researchers at the University of Michigan Comprehensive Cancer Center. The ... had their ovaries removed or took the anti-estrogen drug tamoxifen ...
Other Medicine News:Health News:Spurious Drugs is a Leading Cause of Casualties Among Drug Users 2Health News:Earlier Introduction of Solid Foods in Infants Could Prevent Wheat Allergy 2Health News:Breast-Sparing Surgery: An Optional Treatment Mode For Women With Breast Cancer 2Health News:Breast-Sparing Surgery: An Optional Treatment Mode For Women With Breast Cancer 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: